Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 273

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 273
---
 for the periods indicated (in thousands):

|                                                                       |     | 2024 | Nine Months Ended 
     September 30, |   |     | 2023 |         |   |     | 2023 | Year Ended December 31, |   |     | 2022 |          |   |
|:----------------------------------------------------------------------|:----|:-----|------------------:|:--|:----|:-----|--------:|:--|:----|:-----|------------------------:|:--|:----|:-----|---------:|:--|
| Net cash used in operating activities                                 |     | $    |           (44,497 | ) |     | $    | (50,019 | ) |     | $    |                 (59,663 | ) |     | $    |  (49,640 | ) |
| Net cash provided by investing activities                             |     |      |            12,069 |   |     |      |  79,557 |   |     |      |                  83,206 |   |     |      | (132,886 | ) |
| Net cash provided by financing activities                             |     |      |                77 |   |     |      |     246 |   |     |      |                     326 |   |     |      |   72,620 |   |
| Net (decrease) increase in cash, cash equivalents and restricted cash |     | $    |           (32,351 | ) |     | $    |  29,784 |   |     | $    |                  23,869 |   |     | $    | (109,906 | ) |

Operating Activities Our cash used in operating activities primarily results from our net loss adjusted for non-cashexpenses, changes in working capital components, amounts due to contract research organizations to conduct our clinical programs and employee-related expenditures for research and development and general and administrative activities. Our cash flows from operating activities will continue to be affected by spending to advance and support FYARRO and other operating and general administrative activities, including operating as a public company, and may fluctuate significantly from quarter-to-quarterand year-to-year,depending on our strategic review and the ultimate outcome of that process. For the nine months ended September 30, 2024, cash used in operating activities was $44.5 million and resulted from (i) our net loss of $45.4 million, (ii) $7.